midazolam has been researched along with ro13-9904 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| van Dalen, R; Vree, TB | 1 |
| Kooistra-Smid, AMDM; Rossen, JWA; Schijvens, AM; Schreuder, MF; van de Kar, NCAJ; Wijnsma, KL | 1 |
2 other study(ies) available for midazolam and ro13-9904
| Article | Year |
|---|---|
Pharmacokinetics of antibiotics in critically ill patients.
Topics: Aminoglycosides; Anti-Bacterial Agents; Ceftazidime; Ceftriaxone; Clinical Protocols; Critical Care; Metabolic Clearance Rate; Midazolam; Protein Binding; Tissue Distribution | 1990 |
Unusual severe case of hemolytic uremic syndrome due to Shiga toxin 2d-producing E. coli O80:H2.
Topics: Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Biopsy; Blood Culture; Ceftriaxone; Escherichia coli Infections; Hemolytic-Uremic Syndrome; Humans; Infant; Liver; Magnetic Resonance Imaging; Male; Midazolam; Multiple Organ Failure; Real-Time Polymerase Chain Reaction; Resuscitation; Serotyping; Shiga Toxin 2; Shiga-Toxigenic Escherichia coli; Thrombotic Microangiopathies; Virulence | 2017 |